Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Boris Maleshev who wrote (3683)	11/8/2000 12:55:45 PM
From: Marty R	Read Replies (1) \| Respond to of 5665

As I understand it the presentation regarding huC242-DM1 doesn't occur until Friday. But, because we're talking Amsterdam time PR will therefore come out pre-market Friday similar to what we saw this morning. There was someone on RB this morning who's over at the Amsterdam conference. He/she said there seemed to be a lot of interest at the IMGN poster for huN901-DM1 and he thought PR about huC242-DM1 could come out as early as tomorrow. We'll have to see. But, there should definitely be another announcement.

To: Boris Maleshev who wrote (3683)	11/8/2000 2:05:55 PM
From: Carson O. Ray, Jr.	Read Replies (1) \| Respond to of 5665

C242 Summary at aacr.edoc.com From presentations Index at Proceedings of the 11th NCI·EORTC·AACR Symposium on New Drugs in Cancer Therapy web site (list at aacr.edoc.com Bottom Line: Preliminary pharmacokinetic data (ELISA) at the 88 mg/m2 dose level demonstrated a mean (±SD) peak plasma concentration 99.3 ± 29.9 µg/mL and a prolonged elimination half-life averaging 44 hours. No evidence of human anti-human antibody formation has been detected and dose escalation continues. One patient (88 mg/m2) with pancreatic carcinoma has had stable disease over 5 courses of therapy. So far, SB-408075 can be safely administered IV once every 21 days at doses consistent with impressive activity in preclinical models.